Drugmaker Novavax Begins Late-stage Vaccine Trial In UK2Photo© financialexpress.com

Drugmaker Novavax Begins Late-stage Vaccine Trial In UK

, 6 news, a view

LONDON: U.S.-based Novavax has begun a late stage trial of its potential COVID-19 vaccine in the United Kingdom because the high-level of the coronavirus circulating in the country is likely to produce quick results, the pharmaceutical company said.

Novavax plans to test the effectiveness of its vaccine in a trial involving 10,000 people between the ages of 18 and 84, according to a statement issued late Thursday. At least 25% of the subjects will be over the age of 65, and 400 participants will also receive a licensed flu vaccine.

The trial is being conducted in partnership with the U.K. governments Vaccine Taskforce, which was created in April to help speed the development of a COVID-19 vaccine.